IPC to distribute AP's Promescent in US for treatment of premature ejaculation

The Independent Pharmacy Cooperative (IPC) and Absorption Pharmaceuticals (AP) have signed a distribution agreement whereby IPC will make AP's topical treatment for premature ejaculation, Promescent, available to its 4,500+ member pharmacies throughout the United States.

Promescent is fast becoming first-line therapy for premature ejaculation by numerous urologists and Large Urology Groups Practice Association (LUGPA) members across the U.S., replacing off-label medications which have known side effects. Promescent is available over-the-counter by way of FDA monograph 21 CFR 348.10 and has minimal risk of systemic side effects. The effectiveness, ease-of-use, safety, and low cost per dose of the medication are key reasons for its rise in popularity among physicians.

"Urologists want their patients to have convenient and private locations for obtaining Promescent after their office visit," says Jeff Abraham, CEO of Absorption Pharmaceuticals. "The relationship with IPC now gives patients in virtually every location in the country the fast and confidential access to what has become a mainstream medication for PE."

Many independent pharmacies provide compounding services such as Trimix for erectile dysfunction.  Some urologists who prescribe Trimix and other injection therapies for ED are recommending Promescent to these patients in order to achieve a better overall sexual experience.

"We have witnessed a steady growth in product demand since our first member pharmacy started  carrying Promescent," says Dean Slaugenhoup, director of contracts and purchasing at IPC . "Our mission at IPC is to provide our members cost-effective and convenient access to products that have passed a threshold of acceptance by physicians and Promescent is now clearly in this category. It was time to formalize the relationship."

IPC is now stocking Promescent at its two distribution centers and making members aware of the Promescent's availability.